Intravenous administration of an oxygen-enabled fluid

• US 9,649,335 B1
• Filed: 06/15/2016
• Issued: 05/16/2017
• Est. Priority Date: 03/30/2016
• Status: Active Grant

• Current Assignee: Baylor University
• Original Assignee: Baylor University
• Inventors: Bruce, Erica D., Sayes, Christie, Woodmansee, Jr., John W.
• Primary Examiner(s): Arnold, Ernst V
• Assistant Examiner(s): Chang, Kyung Sook
• Application Number:
  US15/183,403
• Time in Patent Office: 335 Days
• Field of Search: None
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/08 Oxides; Hydroxides
• CPC Class Codes: A61K 47/6949 inclusion complexes, e.g. clathrates, cavitates or fullerenes
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0026 Blood substitute; Oxygen transporting formulations; Plasma extender
• CPC Class Codes: A61K 9/1682 Processes
• CPC Class Codes: A61K 9/5115 Inorganic compounds
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C01F 7/02 Aluminium oxide; Aluminium hydroxide; Aluminates
• CPC Class Codes: C01F 7/023 Grinding, deagglomeration or disintegration
• CPC Class Codes: C01P 2004/61 Micrometer sized, i.e. from 1-100 micrometer
• CPC Class Codes: C01P 2004/62 Submicrometer sized, i.e. from 0.1-1 micrometer
• CPC Class Codes: Y10S 977/773 Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Abstract

A method of treating a condition of a mammal, including a human individual and an animal, by intravenously administering a therapeutically effective amount of a poly-oxygenated metal hydroxide. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm. The poly-oxygenated metal hydroxide may be 75-90% colloid or crystalline solution with 10-25% addition of poly-oxygenated metal hydroxide particles.

Claims

1. A method of oxygenating a human individual, comprising:

intravenously administering a poly-oxygenated aluminum hydroxide composition to the individual, wherein the poly-oxygenated aluminum hydroxide composition comprises a clathrate containing free oxygen gas (O₂) molecules that oxygenate the human individual.

2. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition is water soluble.

3. The method as specified in claim 1 wherein the clathrate comprises particles having a diameter of less than or equal to 1 um.

4. The method as specified in claim 3 wherein the poly-oxygenated aluminum hydroxide composition is water soluble.

5. The method as specified in claim 1 wherein the clathrate comprises particles having a diameter of less than or equal to 100 nm.

6. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition is 75-90% colloid or crystalline solution with 10-25% addition of poly-oxygenated aluminum hydroxide comprising a clathrate containing free oxygen gas (O₂) molecules.

7. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition has a concentration range of 0.1 mg/l to 1000 g/l.

8. The method as specified in claim 1 wherein the poly-oxygenated aluminum hydroxide composition has particles that are surface modified.

9. The method as specified in claim 3 wherein the administration of the poly-oxygenated aluminum hydroxide composition compensates for a depletion of hemoglobin in the human individual.

10. The method as specified in claim 9 wherein the poly-oxygenated aluminum hydroxide composition comprises an oxygen resuscitative fluid.

11. A method of treating a condition of a mammal, comprising:

intravenously administering the mammal a therapeutically effective amount of a poly-oxygenated aluminum hydroxide composition, wherein poly-oxygenated aluminum hydroxide composition comprises a clathrate containing free oxygen gas (O₂) molecules that treat the condition of the mammal.

12. The method as specified in claim 11 wherein the mammal is a human individual.

13. The method as specified in claim 11 wherein the poly-oxygenated aluminum hydroxide composition is water soluble.

14. The method as specified in claim 11 wherein the clathrate comprises particles having a diameter of less than or equal to 1 um.

15. The method as specified in claim 11 wherein the clathrate comprises particles having, a diameter of less than or equal to 100 nm.

16. The method as specified in claim 11 wherein the poly-oxygenated aluminum hydroxide composition is 75-90% colloid or crystalline solution with 10-25% addition of poly-oxygenated aluminum hydroxide comprising a clathrate containing free oxygen gas (O₂) molecules.

17. The method as specified in claim 11 wherein the poly-oxygenated aluminum hydroxide composition has a concentration range of 0.1 mg/l to 1000 mg/l.

18. The method as specified in claim 11 wherein the poly-oxygenated aluminum hydroxide composition has particles that are surface modified.

19. The method as specified in claim 11 wherein the condition is a depletion of hemoglobin in the mammal.

20. The method as specified in claim 19 wherein the poly-oxygenated aluminum hydroxide composition comprises an oxygen resuscitative fluid.